Answers are grounded in this paper and cite their sources.
gene was focally amplified across 20 types of common cancers. Combination with BETi could greatly expand the utility of PARP inhibition to patients with HR-proficient cancer.
No takes yet. Share an insight, caveat, or question.
Yang et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: